0001179110-19-006055.txt : 20190515 0001179110-19-006055.hdr.sgml : 20190515 20190515072144 ACCESSION NUMBER: 0001179110-19-006055 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190513 FILED AS OF DATE: 20190515 DATE AS OF CHANGE: 20190515 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Coleman Mark CENTRAL INDEX KEY: 0001658379 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37635 FILM NUMBER: 19825066 MAIL ADDRESS: STREET 1: 25 BROADWAY STREET 2: 9TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10004 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Axsome Therapeutics, Inc. CENTRAL INDEX KEY: 0001579428 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 454241907 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 200 BROADWAY, 3RD FLOOR CITY: NEW YORK STATE: NY ZIP: 10038 BUSINESS PHONE: (212) 332-3241 MAIL ADDRESS: STREET 1: 200 BROADWAY, 3RD FLOOR CITY: NEW YORK STATE: NY ZIP: 10038 4 1 edgar.xml FORM 4 - X0306 4 2019-05-13 0 0001579428 Axsome Therapeutics, Inc. AXSM 0001658379 Coleman Mark C/O AXSOME THERAPEUTICS, INC. 200 BROADWAY, 3RD FLOOR NEW YORK NY 10038 1 0 0 0 Common Stock 2019-05-13 4 P 0 4650 21.44 A 652648 D Common Stock 5100 I See Footnote The price reported in Column 4 is an average price. These shares were purchased by the reporting person in multiple transactions at prices ranging from $21.42 to $21.49, inclusive. The reporting person undertakes to provide to Axsome Therapeutics, Inc., the staff of the Securities and Exchange Commission, and others pursuant to applicable securities laws, upon request, full information regarding the number of shares sold at each price within the ranges set forth in footnote (1) to this Form 4. Represents additional shares held indirectly by the reporting person prior to May 13, 2019. See Footnote 3. Such shares were purchased by an entity, of which the reporting person has voting and dispositive power, and therefore, the reporting person is deemed to be the indirect beneficial owner of such shares. /s/ Mark Coleman 2019-05-15